17,261 trials
Estrogen Receptor Negative · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Overall Response Rate (ORR) in Patients With Metastatic HER2 Negative Breast Cancer Treated With Durvalumab in Combination With Tremelimumab — 4 participants
Pancreatic Adenocarcinoma Non-resectable · Pancreatic Adenocarcinoma Metastatic · Colorectal Cancer Metastatic
Primary: Overall Survival - Based on Most Recent Scan — 4.66; 7.7 months
Oligometastases
Primary: Percentage of Participants With Freedom From Local Progression (FFLP) — 78.4 percentage of participants
Waldenström Macroglobulinemia
Primary: Overall Response Rate — 3 Participants
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 9; 10; 15; 17 participants
COVID-19
Primary: Duration Until Viral Shedding Cessation — 7; 7 days — p=0.29
Adenoid Cystic Carcinoma
Primary: Patients Demonstrating Objective Response In Non-Irradiated Lesions (Tumor Size on Scans) — 0; 0 Participants
Sanfilippo Syndrome Type A (MPS IIIA)
Primary: Safety as Measured by Adverse Events Frequencies (by Type and Severity) — 53; 128; 0; 1 number of events
Alcohol Drinking
Primary: mL Per 15 Minutes — 85.850; 80.575; 114.104 mls of alcohol consumed per 15 minutes
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Untreated Chronic Lymphocytic Leukemia
Primary: Participants With a Clinical Response — 0 Participants
Recurrent Breast Cancer · Metastatic Breast Cancer
Primary: Ruxolitinib Maximum Tolerated Dose (MTD) [Phase I] — 15 mg
Proliferative Diabetic Retinopathy
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0; 0 Participants
Advanced Non-Clear Cell Kidney Cancer
Primary: Best Overall Response Rate — 33 percentage of participants
Atopic Dermatitis
Primary: Baseline of Disease Characteristics Before Treatment With SUN13834 or Placebo in Adult Participants With Atopic Dermatitis — 12.59; 12.45; 6.01; 3.0 score on a scale
Hepatobiliary Disorders · Non-alcoholic Steatohepatitis
Primary: Percentage of Participants With Non- Alcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 72 Weeks (Yes/No) — 40.4; 35.6; 58.9; 17.2…